1.1 Nalmefene is recommended within its marketing authorisation, as an option for reducing alcohol consumption, for people with alcohol dependence:
who have a high drinking risk level (defined as alcohol consumption of more than 60 g per day for men and more than 40 g per day for women, according to the World Health Organization's drinking risk levels) without physical withdrawal symptoms and
who do not require immediate detoxification.
The marketing authorisation states that nalmefene should:
only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption and
be initiated only in patients who continue to have a high drinking risk level 2 weeks after initial assessment.